563 related articles for article (PubMed ID: 33147621)
21. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
[TBL] [Abstract][Full Text] [Related]
22. The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease.
Shohamy D; Myers CE; Grossman S; Sage J; Gluck MA
Behav Brain Res; 2005 Jan; 156(2):191-9. PubMed ID: 15582105
[TBL] [Abstract][Full Text] [Related]
23. Ventral striatal network connectivity reflects reward learning and behavior in patients with Parkinson's disease.
Petersen K; Van Wouwe N; Stark A; Lin YC; Kang H; Trujillo-Diaz P; Kessler R; Zald D; Donahue MJ; Claassen DO
Hum Brain Mapp; 2018 Jan; 39(1):509-521. PubMed ID: 29086460
[TBL] [Abstract][Full Text] [Related]
24. Distinct effects of apathy and dopamine on effort-based decision-making in Parkinson's disease.
Le Heron C; Plant O; Manohar S; Ang YS; Jackson M; Lennox G; Hu MT; Husain M
Brain; 2018 May; 141(5):1455-1469. PubMed ID: 29672668
[TBL] [Abstract][Full Text] [Related]
25. Non-dopaminergic treatments for motor control in Parkinson's disease.
Fox SH
Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
[TBL] [Abstract][Full Text] [Related]
26. Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients.
Bódi N; Kéri S; Nagy H; Moustafa A; Myers CE; Daw N; Dibó G; Takáts A; Bereczki D; Gluck MA
Brain; 2009 Sep; 132(Pt 9):2385-95. PubMed ID: 19416950
[TBL] [Abstract][Full Text] [Related]
27. Drugs for Parkinson's disease.
Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
[TBL] [Abstract][Full Text] [Related]
28. New directions in the drug treatment of Parkinson's disease.
Montastruc JL; Rascol O; Senard JM
Drugs Aging; 1996 Sep; 9(3):169-84. PubMed ID: 8877311
[TBL] [Abstract][Full Text] [Related]
29. Dopamine depletion impairs gait automaticity by altering cortico-striatal and cerebellar processing in Parkinson's disease.
Gilat M; Bell PT; Ehgoetz Martens KA; Georgiades MJ; Hall JM; Walton CC; Lewis SJG; Shine JM
Neuroimage; 2017 May; 152():207-220. PubMed ID: 28263926
[TBL] [Abstract][Full Text] [Related]
30. Parkinson's disease: making the diagnosis, selecting drug therapies.
Scharre DW; Mahler ME
Geriatrics; 1994 Oct; 49(10):14-6, 20-3. PubMed ID: 7926845
[TBL] [Abstract][Full Text] [Related]
31. Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class.
Bliwise DL; Trotti LM; Wilson AG; Greer SA; Wood-Siverio C; Juncos JJ; Factor SA; Freeman A; Rye DB
Mov Disord; 2012 Aug; 27(9):1118-24. PubMed ID: 22753297
[TBL] [Abstract][Full Text] [Related]
32. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.
Sieradzan K; Channon S; Ramponi C; Stern GM; Lees AJ; Youdim MB
J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):51S-59S. PubMed ID: 7593732
[TBL] [Abstract][Full Text] [Related]
33. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients.
Katayama Y; Kasai M; Oshima H; Fukaya C; Yamamoto T; Ogawa K; Mizutani T
J Neurosurg; 2001 Aug; 95(2):213-21. PubMed ID: 11780890
[TBL] [Abstract][Full Text] [Related]
34. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
Metman LV; Gillespie M; Farmer C; Bibbiani F; Konitsiotis S; Morris M; Shill H; Bara-Jimenez W; Mouradian MM; Chase TN
Clin Neuropharmacol; 2001; 24(3):163-9. PubMed ID: 11391128
[TBL] [Abstract][Full Text] [Related]
35. Dysfunctional inhibitory control in Parkinson's disease patients with levodopa-induced dyskinesias.
Picazio S; Ponzo V; Caltagirone C; Brusa L; Koch G
J Neurol; 2018 Sep; 265(9):2088-2096. PubMed ID: 29980853
[TBL] [Abstract][Full Text] [Related]
36. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
Cools R
Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
[TBL] [Abstract][Full Text] [Related]
37. [Not Available].
Grabli D
Presse Med; 2017 Mar; 46(2 Pt 1):187-194. PubMed ID: 28233705
[TBL] [Abstract][Full Text] [Related]
38. An approach to the continuous dopaminergic stimulation in Parkinson's disease.
Schwartz M; Sabetay S
Isr Med Assoc J; 2012 Mar; 14(3):175-9. PubMed ID: 22675859
[TBL] [Abstract][Full Text] [Related]
39. Pathophysiology of motor fluctuations in Parkinson's disease.
Widnell K
Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
[TBL] [Abstract][Full Text] [Related]
40. Cognitive Stress Reduces the Effect of Levodopa on Parkinson's Resting Tremor.
Zach H; Dirkx MF; Pasman JW; Bloem BR; Helmich RC
CNS Neurosci Ther; 2017 Mar; 23(3):209-215. PubMed ID: 28071873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
